Evidence map›Paper›PMID 23319240›Full record

ArticleEuropean journal of pediatrics2013

Relation between biomarkers and clinical severity in patients with Smith-Lemli-Opitz syndrome.

Anna V Oláh, Gabriella P Szabó, József Varga, Lídia Balogh, Györgyi Csábi, Violetta Csákváry, Wolfgang Erwa, István Balogh

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in European journal of pediatrics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Statins for Smith-Lemli-Opitz syndrome.The Cochrane database of systematic reviews · 2022
    Pooled it
  2. Article
  3. Assessing Postnatal Mortality in Smith-Lemli-Opitz Syndrome.American journal of medical genetics. Part A · 2025
    Observational
  4. Review
  5. Article
  6. Article
  7. Article
  8. Statins for Smith-Lemli-Opitz syndrome.The Cochrane database of systematic reviews · 2020
    Article
  9. Vulnerability ofJournal of lipid research · 2017
    Article
  10. NovelHuman genome variation · 2017
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Anna V OláhDepartment of Laboratory Medicine, Medical and Health Science Center, University of Debrecen, 98 Nagyerdei krt., Debrecen 4032, Hungary. olaha@med.unideb.hu
Gabriella P Szabó
József Varga
Lídia Balogh
Györgyi Csábi
Violetta Csákváry
Wolfgang Erwa
István Balogh
University of Debrecen · HUMarkusovszky Egyetemi Oktatókórház · HUMedical University of Graz · ATSemmelweis University · HUUniversity of Pecs · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledSmith-Lemli-Opitz syndrome (SLOS), a multiple congenital anomaly with severe mental retardation, is caused by decreased activity of 7-dehydrocholesterol reductase. Fifteen Hungarian patients were diagnosed with SLOS on the basis of clinical symptoms, serum cholesterol, 7-dehydrocholesterol, and molecular genetic testing. Their age at the time of diagnosis in mild SLOS (n = 4, clinical score <20) was 0.5-18 years, cholesterol was 2.37 ± 0.8 mmol/L, and 7DHC was 0.38 ± 0.14 mmol/L. In the group of typical SLOS (n = 7, score 20-50), the diagnosis was set up earlier (age of 0.1-7 years); t-cholesterol was 1.47 ± 0.7 mmol/L, and 7DHC was 0.53 ± 0.20 mmol/L. Patients with severe SLOS (n = 4, clinical score > 50) died as newborns and had the lowest t-cholesterol (0.66 ± 0.27 mmol/L), and 7DHC was 0.47 ± 0.14 mmol/L. Correlation coefficient with clinical severity was 0.74 for initial t-cholesterol and 0.669 for Cho/7DHC. Statistically significant difference was between the initial t-cholesterol of mild and severe SLOS (p = 0.01), and between the Cho/7DHC ratios of groups (p = 0.004). In severe SLOS, the percentage of α-lipoprotein was significantly lower than in typical (p = 0.003) and mild SLOS (p = 0.004). Although serum albumin, total bilirubin, and hemostasis parameters remained in the reference range during cholesterol supplementation (n = 10) combined with statin therapy (n = 9), increase of aspartate aminotransferase and alanine aminotransferase in 50 % of the patients probably refers to a reversible alteration of liver function; therefore, statin therapy was suspended.

conclusionlife expectancy is fundamentally determined by the initial t-cholesterol, but dehydrocholesterol and α-lipoprotein have prognostic value. Accumulation of hepatotoxic DHC may inhibit the synthesis of α-lipoproteins, decreasing the reverse cholesterol transport. During statin therapy, we suggest monitoring of lipid parameters and liver function.

Indexed as

AdolescentBiomarkersChildChild, PreschoolCholesterolDehydrocholesterolsFemaleHumansHungaryInfantLipoproteins, HDLLiver Function TestsMaleSeverity of Illness IndexSmith-Lemli-Opitz SyndromeBiomarkersCholesterolDehydrocholesterolsLipoproteins, HDL

Identifiers

PMID23319240
OpenAlexW1976959243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.